Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Geraldine Faivre; Matthew James Butler; Isabelle Le; Andrew Brenner

doi:10.1016/j.clml.2019.05.012

Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Geraldine Faivre, Matthew James Butler, Isabelle Le, Andrew Brenner

Producción científica: Article › revisión exhaustiva

10 Citas (Scopus)

Resumen

Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

Idioma original	English (US)
Páginas (desde-hasta)	665-669
Número de páginas	5
Publicación	Clinical Lymphoma, Myeloma and Leukemia
Volumen	19
N.º	10
DOI	https://doi.org/10.1016/j.clml.2019.05.012
Estado	Published - oct 2019

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Acceder al documento

10.1016/j.clml.2019.05.012

Otros archivos y enlaces

Citar esto

@article{692f4ba23e8a4effbc8b99e142d91c83,

title = "Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma",

abstract = "Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.",

keywords = "Consolidation, MTX, PCNSL, R-MPV, TMZ",

author = "Geraldine Faivre and Butler, {Matthew James} and Isabelle Le and Andrew Brenner",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = oct,

doi = "10.1016/j.clml.2019.05.012",

language = "English (US)",

volume = "19",

pages = "665--669",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "10",

}

TY - JOUR

T1 - Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

AU - Faivre, Geraldine

AU - Butler, Matthew James

AU - Le, Isabelle

AU - Brenner, Andrew

PY - 2019/10

Y1 - 2019/10

N2 - Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

AB - Optimal management of elderly patients with primary central nervous system lymphoma (PCNSL) after induction therapy is unclear. In our retrospective series of 10 patients treated with temozolomide after induction with R-MPV (rituximab, methotrexate, procarbazine and vincristine) we found a median progression-free survival of 57 months, and a median overall survival of 63 months, with moderate toxicity, which supports the idea that temozolomide might have activity for maintenance in elderly patients with PCNSL.

KW - Consolidation

KW - MTX

KW - PCNSL

KW - R-MPV

KW - TMZ

UR - http://www.scopus.com/inward/record.url?scp=85069726281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069726281&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2019.05.012

DO - 10.1016/j.clml.2019.05.012

M3 - Article

C2 - 31351990

AN - SCOPUS:85069726281

SN - 2152-2650

VL - 19

SP - 665

EP - 669

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 10

ER -

Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto